EXTERNALLY-LED PATIENT-FOCUSED DRUG DEVELOPMENT WORKSHOPS ON CHILDHOOD CANCER

SEPTEMBER 15, 2022

Survivors who experience cardiac effects have a serious and chronic burden of disease that can increase with age and impact long-term well-being. This conference is an important opportunity for survivors and caregivers to educate representatives of the Food and Drug Administration (FDA) and other stakeholders about personal experiences managing the impact of cardiac late effects on daily living and long-term health.

September 13, 2018

The pediatric patient population with chemotherapy-induced hearing loss represents a segment of the cancer survivor community with a severe burden of disease with great unmet medical need. An externally-led, FDA-approved Patient Focused Drug Development (PFDD) meeting was held in 2018 near Washington, DC to explore these issues in-depth.